Show simple item record

dc.contributor.authorHall, E
dc.contributor.authorCameron, D
dc.contributor.authorWaters, R
dc.contributor.authorBarrett-Lee, P
dc.contributor.authorEllis, P
dc.contributor.authorRussell, S
dc.contributor.authorBliss, JM
dc.contributor.authorHopwood, P
dc.contributor.authorTACT Trial Investigators
dc.date.accessioned2020-08-13T11:47:52Z
dc.date.issued2014-09
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2014, 50 (14), pp. 2375 - 2389
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3953
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2014.06.007
dc.description.abstractBackground The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a median of 5 years suggested no improvement in disease-free survival with FEC-D. Given differing toxicity profiles of the regimens, the impact on quality of life (QL) was explored.Methods Patients from 44 centres completed standardised QL questionnaires before chemotherapy, after cycles 4 and 8, at 9, 12, 18 and 24 months and at 6 years follow-up. Patient diaries assessed frequency, associated distress and impact on daily activity of 15 treatment related side effects.Findings 830 patients (415 FEC-D; 415 controls) contributed assessments during 0-24 months; 362 of whom participated again at 6 years. During chemotherapy, FEC-D impaired global health/QL and depression rates and significantly more QL domains than standard regimens. Novel diary card ratings highlighted significantly more distress and interference with daily activities due to FEC-D side effects compared with standard treatment. In both groups, most QL parameters returned to baseline levels by 2 years and were unchanged at 6 years.Interpretation Within expected negative effects of chemotherapy on wide ranging QL domains FEC-D patients reported greater toxicity, disruption and distress during treatment with no improvement in disease outcome at 5 years than patients receiving standard anthracycline-based chemotherapy. Findings should inform future patients of relative costs and benefits of adjuvant chemotherapy.
dc.formatPrint-Electronic
dc.format.extent2375 - 2389
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectTACT Trial Investigators
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectTaxoids
dc.subjectTamoxifen
dc.subjectCyclophosphamide
dc.subjectFluorouracil
dc.subjectMethotrexate
dc.subjectAnthracyclines
dc.subjectEpirubicin
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectTherapeutics
dc.subjectChemotherapy, Adjuvant
dc.subjectQuality of Life
dc.subjectAdult
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectSurveys and Questionnaires
dc.subjectUnited Kingdom
dc.subjectBridged-Ring Compounds
dc.titleComparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
dc.typeJournal Article
dcterms.dateAccepted2014-06-08
rioxxterms.versionofrecord10.1016/j.ejca.2014.06.007
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2014-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.issue14
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.publication-statusPublished
pubs.volume50
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Uniten_US
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
dc.contributor.icrauthorBliss, Judithen
dc.contributor.icrauthorHall, Emmaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0